CAR-T cells for relapsed B-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have B-cell acute lymphoblastic leukemia (ALL) or a type of B-cell non-Hodgkin lymphoma (such as diffuse large B-cell lymphoma, mantle cell lymphoma, etc.) that has come back or not improved after standard treatments.
- You are willing to sign a consent form and follow all study procedures.
- Your overall health is good (ECOG performance status 0-2) and you are expected to live at least 12 weeks.
- Your blood counts and organ function (kidney, liver, heart, lungs) meet certain minimum levels, and you have no active serious infections or other cancers.
- You have not had a previous CAR-T cell therapy or certain other treatments within a specified time frame.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a personalized CAR-T cell treatment that targets a marker called CD79b in people whose B-blood cancers have come back or not responded to prior treatment. It may help your immune system find and attack cancer cells, but it also requires you to meet safety and health criteria.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.